Reports
Reports
The global bronchiectasis drugs market size is projected to expand by USD 126.75 million between 2021 and 2026.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Conventional techniques used to diagnose bacterial lung infection have several constraints, including failure to accurately identify the cause of infection and failure to provide a full representation of the bacterial load present in the lungs, thus, leading to the development of advanced technologies like high-resolution computed tomography (HRCT) scan, aiding the bronchiectasis drugs market. Further, the availability of low-cost drugs is one of the major factors aiding the bronchiectasis drugs industry, globally.
Bronchiectasis can lead to a build-up of excess mucous, making the lungs more vulnerable to infection. The major method to treat bronchiectasis remains the use of antibiotics to avoid infection.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The industry can be broadly categorised on the basis of its product into:
The EMR report looks into the regional bronchiectasis drugs markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
The high-resolution computed tomography (HRCT) scan has emerged as popular technique to diagnose bronchiectasis and other respiratory diseases. Such developments in respiratory disease diagnostics will allow pulmonologists and otolaryngologists to accurately define the disease phase and provide patients with suitable and timely therapy and medicines. This trend will have a positive effect over the forecast period on bronchiectasis drugs market growth. Further, the accessibility to low-cost and off-label generic drugs is one of the major factors responsible for the development of the market. Generic drug contains the same active pharmaceutical ingredient (API) as branded drugs and are less expensive than branded drugs. The availability of such low-priced drugs, combined with rising bronchiectasis incidence, will increase therapeutic adoption rates, particularly in underdeveloped and developing countries. The approval of these low-cost generics will further increase the growth opportunities for market.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The report presents a detailed analysis of the following key players in the global bronchiectasis drugs market, looking into their capacity, competitive landscape, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s five forces.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2022 |
Historical Period | 2018-2022 |
Forecast Period | 2023-2028 |
Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Product, Region |
Breakup by Product | Antibiotics, Expectorants, Other Drugs |
Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
Companies Covered | Endo International Plc [ENDP (NASDAQ)], GlaxoSmithKline Plc [GSK (LON)], Neopharma LLC, Pfizer Inc. [PFE (NYSE)], Reckitt Benckiser Group Plc [RB (LON)], Others |
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Bronchiectasis Drugs Market Analysis
8.1 Key Industry Highlights
8.2 Global Bronchiectasis Drugs Historical Market (2018-2022)
8.3 Global Bronchiectasis Drugs Market Forecast (2023-2028)
8.4 Global Bronchiectasis Drugs Market by Product
8.4.1 Antibiotics
8.4.1.1 Historical Trend (2018-2022)
8.4.1.2 Forecast Trend (2023-2028)
8.4.2 Expectorants
8.4.2.1 Historical Trend (2018-2022)
8.4.2.2 Forecast Trend (2023-2028)
8.4.3 Other Drugs
8.5 Global Bronchiectasis Drugs Market by Region
8.5.1 North America
8.5.1.1 Historical Trend (2018-2022)
8.5.1.2 Forecast Trend (2023-2028)
8.5.2 Europe
8.5.2.1 Historical Trend (2018-2022)
8.5.2.2 Forecast Trend (2023-2028)
8.5.3 Asia Pacific
8.5.3.1 Historical Trend (2018-2022)
8.5.3.2 Forecast Trend (2023-2028)
8.5.4 Latin America
8.5.4.1 Historical Trend (2018-2022)
8.5.4.2 Forecast Trend (2023-2028)
8.5.5 Middle East and Africa
8.5.5.1 Historical Trend (2018-2022)
8.5.5.2 Forecast Trend (2023-2028)
9 North America Bronchiectasis Drugs Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2022)
9.1.2 Forecast Trend (2023-2028)
9.2 Canada
9.2.1 Historical Trend (2018-2022)
9.2.2 Forecast Trend (2023-2028)
10 Europe Bronchiectasis Drugs Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2022)
10.1.2 Forecast Trend (2023-2028)
10.2 Germany
10.2.1 Historical Trend (2018-2022)
10.2.2 Forecast Trend (2023-2028)
10.3 France
10.3.1 Historical Trend (2018-2022)
10.3.2 Forecast Trend (2023-2028)
10.4 Italy
10.4.1 Historical Trend (2018-2022)
10.4.2 Forecast Trend (2023-2028)
10.5 Others
11 Asia Pacific Bronchiectasis Drugs Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2022)
11.1.2 Forecast Trend (2023-2028)
11.2 Japan
11.2.1 Historical Trend (2018-2022)
11.2.2 Forecast Trend (2023-2028)
11.3 India
11.3.1 Historical Trend (2018-2022)
11.3.2 Forecast Trend (2023-2028)
11.4 ASEAN
11.4.1 Historical Trend (2018-2022)
11.4.2 Forecast Trend (2023-2028)
11.5 Australia
11.5.2 Historical Trend (2018-2022)
11.5.2 Forecast Trend (2023-2028)
11.6 Others
12 Latin America Bronchiectasis Drugs Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2022)
12.1.2 Forecast Trend (2023-2028)
12.2 Argentina
12.2.1 Historical Trend (2018-2022)
12.2.2 Forecast Trend (2023-2028)
12.3 Mexico
12.3.1 Historical Trend (2018-2022)
12.3.2 Forecast Trend (2023-2028)
12.4 Others
13 Middle East and Africa Bronchiectasis Drugs Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2022)
13.1.2 Forecast Trend (2023-2028)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2022)
13.2.2 Forecast Trend (2023-2028)
13.3 Nigeria
13.3.1 Historical Trend (2018-2022)
13.3.2 Forecast Trend (2023-2028)
13.4 South Africa
13.4.1 Historical Trend (2018-2022)
13.4.2 Forecast Trend (2023-2028)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Value Chain Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Company Profiles
16.2.1 GlaxoSmithKline Plc (LON: GSK)
16.2.1.1 Company Overview
16.2.1.2 Product Portfolio
16.2.1.3 Demographic Reach and Achievements
16.2.1.4 Certifications
16.2.2 Neopharma LLC
16.2.2.1 Company Overview
16.2.2.2 Product Portfolio
16.2.2.3 Demographic Reach and Achievements
16.2.2.4 Certifications
16.2.3 Pfizer Inc. (NYSE: PFE)
16.2.3.1 Company Overview
16.2.3.2 Product Portfolio
16.2.3.3 Demographic Reach and Achievements
16.2.3.4 Certifications
16.2.4 Reckitt Benckiser Group Plc (LON: RB)
16.2.4.1 Company Overview
16.2.4.2 Product Portfolio
16.2.4.3 Demographic Reach and Achievements
16.2.4.4 Certifications
16.2.5 Others
17 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Bronchiectasis Drugs Market: Key Industry Highlights, 2018 and 2028
2. Global Bronchiectasis Drugs Historical Market: Breakup by Product (USD Million), 2018-2022
3. Global Bronchiectasis Drugs Market Forecast: Breakup by Product (USD Million), 2023-2028
4. Global Bronchiectasis Drugs Historical Market: Breakup by Region (USD Million), 2018-2022
5. Global Bronchiectasis Drugs Market Forecast: Breakup by Region (USD Million), 2023-2028
6. North America Bronchiectasis Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
7. North America Bronchiectasis Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
8. Europe Bronchiectasis Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
9. Europe Bronchiectasis Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
10. Asia Pacific Bronchiectasis Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
11. Asia Pacific Bronchiectasis Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
12. Latin America Bronchiectasis Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
13. Latin America Bronchiectasis Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
14. Middle East and Africa Bronchiectasis Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
15. Middle East and Africa Bronchiectasis Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
16. Global Bronchiectasis Drugs Market Structure
The global bronchiectasis drugs market is projected to grow by USD 126.75 million between 2021 and 2026.
The major drivers of the market include the development of innovative technologies to diagnose bacterial lung infection and the growing pharmaceutical sector.
The availability of low-cost drugs and the increasing accessibility of generic drugs are key trends propelling the growth of the market.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The leading products in the market are antibiotics, expectorants, and other drugs.
The major players in the market are GlaxoSmithKline Plc, Neopharma LLC, Pfizer Inc., and Reckitt Benckiser Group Plc, among others.
Aided by the rising investments into the healthcare sector, the global bronchiectasis drugs market is expected to witness a healthy growth in the forecast period of 2023-2028 and expand by USD 126.75 million.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on product, the bronchiectasis drugs industry can be segmented into antibiotics, expectorants, and other drugs. The major regional markets for bronchiectasis drugs are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Endo International Plc, GlaxoSmithKline Plc, Neopharma LLC, Pfizer Inc., Reckitt Benckiser Group Plc, and others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.